HIT-LOGGIC

Author:  Julia Dobke, Last modification: 2024/03/27 https://kinderkrebsinfo.de/doi/e209008

HIT-LOGGIC HIT-LOGGIC Registry: Prospective multicenter registry for children and adolescents with a low-grade glioma
Disease low-grade glioma
Type prospective registry
Rationale / Objectives

Low-grade gliomas of childhood and adolescence (LGG) are the most common brain tumors in these age groups and account for approximately 40-50 % of patients in Germany. The median age at diagnosis is between 6-8 years. About 7 % of all patients are diagnosed as infants.
The main purpose of the registry is to collect key characteristics of patients with LGG in Germany, regardless of whether they are included in a clinical trial. The objectives of this registry are manifold:

  • Prospective demographic recording of primary, recurrent and chronic-progressive patients with an LGG
  • Quality assurance by ensuring standardized central referencing of all essential diagnostic steps for all patients, especially if not primarily treated in a clinical trial
  • Ensuring centralized counseling of patients and practitioners
  • Collecting data on the therapies used in the course of treatment for comparison with the treatment results from the preliminary studies and registers
  • Enabling the joint evaluation of the clinical data of patients from the precursor studies and registries with regard to long-term courses
  • Long-term observation of patients who develop LGG in childhood and adolescence
  • Recording of disease- and therapy-associated late effects
  • Creation of a database of clinical data and, in cooperation with the LOGGIC core study, molecular data in order to be able to compare current and future studies (multi-state model)
  • Provision of clinical information in order to be able to retrospectively evaluate subgroups
  • Provision of centralized clinical data from patients with low-grade glioma registered in Germany for current and future national and international collaborations, such as the German Childhood Cancer Registry, the HIT-Life Consortium, the European SIOPE-BTG for Low-Grade Glioma (LOGGIC), the American COG and other partners
  • Provision of central clinical and, in cooperation with the LOGGIC Core Study, biological data in order to be able to refer patients to future Phase I/II/III studies
Therapy / Study arms

Therapeutic interventions are not planned and will be carried out as needed through clinical trial protocols and/or according to the treatment recommendations of the European Working Group on Low-Grade Gliomas in Children and Adolescents.

Inclusion Criteria
  • Diagnosis or suspicion of LGG by examination of tumor material or neuroradiological diagnosis confirmed by the reference center for neuroradiology
  • From birth to 21 years of age
  • Signed informed consent forms depending on the age and cognitive development of the patient and/or legal guardian
Recruitment 300 per year
Status Start 01.01.2019, until further notice
Principal Investigator PD Dr. med. P. Hernaiz Driever,
E-Mail loggic-register@charite.de
Contact

Investigator

PD Dr. med. Pablo Hernáiz Driever Charité-Universitätsmedizin Berlin Augustenburger Platz 1, D- Telefon: 030/450-666829 Fax: 030/450-7566829 Klinik für Pädiatrie m.S. Onkologie/Hämatologie Augustenburger Platz 1 13353 Berlin Telefon +49 (30) 450-666 829 Fax +49 (30) 450 756 6829 pablo.hernaiz@charite.de

Trial Management

Dr. rer. medic. Adriane Napp Charité-Universitätsmedizin Berlin Päd. Klinuik m. S. Onkologie/Hämatologie Augustenburger Platz 1 13353 Berlin Telefon +49 (30) 450666 829 Fax +49 (30) 450 756 6829 loggic-register@charite.de

Cooperation Partner

Prof. Dr. med. Olaf Witt Universität Heidelberg, Hopp-Kindertumorzentrum am NCT Heidelberg (KiTZ) Zentrum für Kinder- und Jugendmedizin & Klinische Kooperationseinheit Päd.Onkologie der Uniklinik Heidelberg und dem DKFZ Im Neuenheimer Feld 430 69120 Heidelberg Telefon +49-6221 42 3570 Fax +49 6221 42 3277 olaf.witt@kitz-heidelberg.de Hopp-Kindertumorzentrum Heidelberg

Sponsoring Deutsche Kinderkrebsstiftung